InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

CompletedLast updated: 7 February 2024

TREATT: This phase III trial is trying to determine whether it is effective to give tranexamic acid (a drug that reduces heavy bleeding) to patients with ThrombocytopeniaA double blind, randomised controlled TRial EvaluAting the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe Thrombocytopenia

Clinical summary

Summary

Patients with cancers of the blood often develop low blood cell counts either as a consequence of the disease or the treatment by chemotherapy or stem cell transplantation. Platelet transfusions are commonly given to raise any low platelet count and reduce the risk of clinical bleeding (prophylaxis) or stop active bleeding (therapy). But recent studies have indicated that many patients continue to experience bleeding, despite the use of platelet transfusions. Tranexamic acid is a type of drug that is called an antifibrinolytic. These drugs act to reduce the breakdown of clots formed in response to bleeding. These drugs have been used widely in both elective and emergency surgery and have been shown to decrease blood loss and the use of red cell transfusions. The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo. We will measure the rates of bleeding daily using a short structured assessment of bleeding, and we will record the number of transfusions given to patients.

Conditions

This trial is treating patients with Essential Thrombocytosis

Cancer

Blood Cancers Haematological

Age

People18 - 75

Phase

III

Trial Acronym

TREATT

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

National Health Service Blood & Transplant

Scientific Title

A double blind, randomised controlled TRial EvaluAting the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe Thrombocytopenia

Eligibility

Inclusion

Patients are eligible for this trial if:

  1. Aged ≥18 years of age
  2. Confirmed diagnosis of a haematological malignancy
  3. Undergoing chemotherapy, or chemotherapy is planned, or haematopoietic stem cell transplantation
  4. Anticipated to have a hypoproliferative thrombocytopenia resulting in a platelet count of ≤10x10⁹/L for ≥ 5 days
  5. Able to comply with treatment and monitoring

Exclusion

A patient will not be eligible for this trial if he/she fulfils one or more of the following criteria:

  1. Patients with a past history or current diagnosis of arterial or venous thromboembolic disease including myocardial infarction, peripheral vascular disease and retinal arterial or venous thrombosis.
  2. Diagnosis of acute promyelocytic leukaemia (APML) and undergoing induction chemotherapy
  3. Patients with a diagnosis/previous history of veno-occlusive disease (also called sinusoidal obstruction syndrome)
  4. Patients with known inherited or acquired prothrombotic disorders e.g.

    1. Lupus anticoagulant
    2. Positive antiphospholipids
  5. Patients receiving any pro-coagulant agents (e.g. DDAVP, recombinant Factor VIIa or Prothrombin Complex Concentrates (PCC) within 48 hours of enrolment, or with known hypercoagulable state
  6. Patients receiving L-asparaginase as part of their current cycle of treatment
  7. History of immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS)
  8. Patients with overt disseminated intravascular coagulation (DIC) (See Appendix 3 in the protocol for definition)
  9. Patients requiring a platelet transfusion threshold >10x10/⁹L at time of randomisation. (This refers to patients who require their platelet count to be maintained at a certain specified level on an ongoing basis, and excludes a transient rise in the threshold due to sepsis.)
  10. Patients with a known inherited or acquired bleeding disorder e.g.

    1. Acquired storage pool deficiency
    2. Paraproteinaemia with platelet inhibition
  11. Patients receiving anticoagulant therapy or anti-platelet therapy
  12. Patients with visible haematuria at time of randomisation
  13. Patients with anuria (defined as urine output < 10 mls/hr over 24 hours).
  14. Patients with severe renal impairment (eGFR ≤30 ml/min/1.73m²)
  15. Patients with a previous history of epilepsy, convulsions, fits or seizures
  16. Patients who are pregnant or breast-feeding
  17. Allergic to tranexamic acid.
  18. Patients enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents.
  19. Patients previously randomised into this trial at any stage of their treatment.

Inclusion

  • You have had a certain type of treatment or surgical procedure.

Exclusion

  • You have certain types of non-cancer medical conditions.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

Completed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.